Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) PT at $9.67

Rezolute, Inc. (NASDAQ:RZLT) has earned an average rating of “Buy” from the six analysts that are presently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have covered the stock in the last year is $9.67.

RZLT has been the subject of a number of research analyst reports. Maxim Group initiated coverage on shares of Rezolute in a research note on Tuesday, April 9th. They issued a “buy” rating and a $8.00 price target for the company. JMP Securities reiterated a “market outperform” rating and set a $7.00 target price on shares of Rezolute in a research note on Thursday, April 18th. HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of Rezolute in a report on Wednesday, May 22nd. Craig Hallum began coverage on Rezolute in a report on Tuesday, June 4th. They issued a “buy” rating and a $14.00 price objective for the company. Finally, Jonestrading initiated coverage on Rezolute in a report on Thursday, April 18th. They issued a “buy” rating and a $10.00 target price on the stock.

Insider Activity

In related news, CFO Daron Evans acquired 40,000 shares of Rezolute stock in a transaction dated Friday, June 14th. The stock was purchased at an average cost of $4.04 per share, for a total transaction of $161,600.00. Following the purchase, the chief financial officer now directly owns 40,000 shares of the company’s stock, valued at approximately $161,600. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders acquired a total of 57,124 shares of company stock valued at $220,314 in the last 90 days. Company insiders own 20.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new position in Rezolute during the first quarter valued at approximately $37,000. Acadian Asset Management LLC bought a new stake in shares of Rezolute during the 1st quarter valued at $229,000. Rosalind Advisors Inc. purchased a new position in shares of Rezolute during the 1st quarter valued at $510,000. Vanguard Group Inc. boosted its holdings in Rezolute by 10.4% in the 1st quarter. Vanguard Group Inc. now owns 1,553,352 shares of the company’s stock worth $3,961,000 after buying an additional 145,700 shares during the period. Finally, Affinity Asset Advisors LLC purchased a new stake in Rezolute in the 1st quarter worth $4,080,000. 82.97% of the stock is currently owned by institutional investors.

Rezolute Price Performance

RZLT stock opened at $4.17 on Friday. The stock has a market capitalization of $167.34 million, a P/E ratio of -3.66 and a beta of 1.20. Rezolute has a 1-year low of $0.72 and a 1-year high of $6.10. The business has a fifty day moving average price of $3.73 and a 200-day moving average price of $2.37.

Rezolute (NASDAQ:RZLT) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.34) EPS for the quarter, hitting the consensus estimate of ($0.34). As a group, analysts anticipate that Rezolute will post -1.15 earnings per share for the current year.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.